NHO Revive opens Nebraska’s only site for Johnson & Johnson prostate cancer trial

NHO Revive in Lincoln is now Nebraska’s only site for a Johnson & Johnson Phase 3 prostate cancer study testing Pasritamig, a T-cell engaging immune therapy. The trial could give patients with advanced disease access to a treatment designed to work differently from chemotherapy and hormone therapy.

Why it matters: - The trial gives Nebraska patients access to a Phase 3 study of a new immune therapy for advanced prostate cancer. - Pasritamig is designed to direct T-cells toward cancer cells that express human kallikrein 2, or KLK2. - The approach could offer another option for patients whose disease has progressed after standard treatments.

What happened: - NHO Revive became Nebraska’s only site for the Johnson & Johnson-sponsored KLK2-PASenger Phase 3 prostate cancer trial. - The study is open in Lincoln through Nebraska Hematology-Oncology and Revive Research Institute. - Dr. Kailash Mosalpura, medical oncologist at Nebraska Hematology-Oncology, said the trial brings innovative treatment options directly to patients in Lincoln.

The details: - The randomized, open-label study compares pasritamig plus docetaxel with docetaxel alone. - The primary endpoint is whether the combination lengthens the time patients live without disease progression on imaging scans. - The study also measures overall survival, quality of life and other response outcomes. - Eligible patients must have histologically confirmed metastatic prostate adenocarcinoma. - Participants must have disease that has progressed despite androgen deprivation therapy and at least one prior novel hormonal therapy. - Eligible patients must be at least 18 years old and have an ECOG performance status of 0 or 1. - NHO Revive is a joint initiative between Nebraska Hematology Oncology and Revive Research Institute. - Nebraska Hematology-Oncology has served Lincoln and surrounding communities since 1997. - NHO says the clinic has seven physicians, 13 advanced practice providers and more than 145 staff. - NHO says the clinic was the first QOPI-certified and Oncology Medical Home APC4-certified clinic in Nebraska. - More information is available at the company’s announcement. - NHO also directs visitors to YourCancerCare.com for more information.

Between the lines: - The trial’s design signals continued interest in combining targeted immune therapy with existing chemotherapy to improve outcomes in metastatic prostate cancer. - Opening the only Nebraska site may help expand access to late-stage clinical research for patients who otherwise would need to travel out of state. - The focus on KLK2 reflects a more precise treatment strategy than broad chemotherapy or hormone-based therapy.

What's next: - Patients who meet the study criteria can seek screening for enrollment. - If the combination therapy outperforms docetaxel alone, the study could support a broader role for pasritamig in prostate cancer care. - NHO Revive is likely to use the site to continue expanding clinical trial access in Lincoln.

The bottom line: - Nebraska patients with advanced prostate cancer now have local access to a Phase 3 trial testing a new immune-based treatment strategy.